Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) FCF Margin (2020 - 2025)

Foghorn Therapeutics has reported FCF Margin over the past 6 years, most recently at 240.85% for Q4 2025.

  • Quarterly results put FCF Margin at 240.85% for Q4 2025, up 63927.0% from a year ago — trailing twelve months through Dec 2025 was 278.72% (up 16953.0% YoY), and the annual figure for FY2025 was 278.72%, up 16953.0%.
  • FCF Margin for Q4 2025 was 240.85% at Foghorn Therapeutics, down from 231.94% in the prior quarter.
  • Over the last five years, FCF Margin for FHTX hit a ceiling of 6920.79% in Q1 2022 and a floor of 50565.85% in Q3 2021.
  • Median FCF Margin over the past 5 years was 440.08% (2025), compared with a mean of 3223.54%.
  • Biggest five-year swings in FCF Margin: crashed -4897200bps in 2021 and later skyrocketed 5027072bps in 2022.
  • Foghorn Therapeutics' FCF Margin stood at 1655.26% in 2021, then tumbled by -142bps to 690.25% in 2022, then soared by 31bps to 477.0% in 2023, then plummeted by -85bps to 880.11% in 2024, then skyrocketed by 73bps to 240.85% in 2025.
  • The last three reported values for FCF Margin were 240.85% (Q4 2025), 231.94% (Q3 2025), and 277.52% (Q2 2025) per Business Quant data.